Your browser doesn't support javascript.
loading
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Yoshino, T; Portnoy, D C; Obermannová, R; Bodoky, G; Prausová, J; Garcia-Carbonero, R; Ciuleanu, T; García-Alfonso, P; Cohn, A L; Van Cutsem, E; Yamazaki, K; Lonardi, S; Muro, K; Kim, T W; Yamaguchi, K; Grothey, A; O'Connor, J; Taieb, J; Wijayawardana, S R; Hozak, R R; Nasroulah, F; Tabernero, J.
Afiliação
  • Yoshino T; National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: tyoshino@east.ncc.go.jp.
  • Portnoy DC; The West Clinic, Memphis, USA.
  • Obermannová R; Masarykuv Onkologicky Ustav, Brno, Czech Republic.
  • Bodoky G; St. Laszlo Hospital, Budapest, Hungary.
  • Prausová J; Fakultni Nemocnice v MOTOLE, Prague, Czech Republic.
  • Garcia-Carbonero R; Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain.
  • Ciuleanu T; Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
  • García-Alfonso P; Hospital General Univ Gregorio Marañón, Madrid, Spain.
  • Cohn AL; Rocky Mountain Cancer Center, LLP, Denver, USA.
  • Van Cutsem E; Univ Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
  • Yamazaki K; Shizuoka Cancer Center, Shizuoka, Japan.
  • Lonardi S; Istituto Oncologico Veneto-IRCCS, Padova, Italy.
  • Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Kim TW; Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.
  • Yamaguchi K; The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Grothey A; Mayo Clinic, Phoenix, USA.
  • O'Connor J; Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Taieb J; Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France.
  • Wijayawardana SR; Eli Lilly and Company, Indianapolis, USA.
  • Hozak RR; Eli Lilly and Company, Indianapolis, USA.
  • Nasroulah F; Eli Lilly and Company, Buenos Aires, Argentina.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
Ann Oncol ; 30(1): 124-131, 2019 01 01.
Article em En | MEDLINE | ID: mdl-30339194
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Proteínas ras / Proteínas Proto-Oncogênicas c-raf / Mutação / Neovascularização Patológica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Proteínas ras / Proteínas Proto-Oncogênicas c-raf / Mutação / Neovascularização Patológica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article